High-Dose intravenous immunoglobulin is effective in painful diabetic polyneuropathy resistant to conventional treatments. Results of a double-blind, randomized, placebo-controlled, multicenter trial
Objectives: The efficacy and safety of high-dose intravenous immunoglobulin (IVIG) in treatment-resistant diabetic painful polyneuropathy (DPN) were assessed. Design: This was a randomized, double-blind, placebo-controlled, multicenter trial (EudraCT 2010-023883-42). Setting: This trial was conducted at eight sites in Italy with a neurology specialist level of care.